© 2004 European Society for Medical Oncology
Original Article |
Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing
1 Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale; 2 Department of Medical Oncology, I.F.O., Rome; 3 Chair of Hematology, University of Rome ‘Tor Vergata’, Rome, Italy
* Correspondence to: Dr R. Stasi, Department of Medical Sciences, Regina Apostolorum Hospital, Via S. Francesco 50, 00041 Albano Laziale, Italy. Tel: +39-06-932989; Fax: +39-06-233231809; Email: roberto.stasi{at}uniroma2.it
Background: Once-weekly dosing of recombinant human erythropoietin (rhEPO) in patients with myelodysplastic syndromes (MDS) has not been investigated thoroughly. We performed a clinical trial to evaluate the effects of this new dosing regimen in patients with MDS who were unresponsive to the conventional three-times-weekly schedule.
Patients and methods: Forty-eight patients with low- or intermediate-risk MDS were enrolled in a 12-week study. rhEPO alpha (rhEPO
) was administered once-weekly by subcutaneous injection with a starting dose of 40 000 U fixed dose. The drug dosage was increased to 60 000 U fixed dose if after 6 weeks there was no or suboptimal erythroid response.
Results: Clinically significant responses were seen in 13 (27%) patients, with 11 improving their response after dose escalation of rhEPO. Only one patient (case 23) maintains a response after a follow-up period of 14 months. All other patients had responses lasting between 10 and 43 weeks, with a median time to relapse of 20 weeks. Treatment was well tolerated, with no relevant adverse events. Response to therapy was associated with significantly higher concentrations of circulating erythroid blast-forming units and a decrease of the bone marrow fraction of apoptic CD34+ cells.
Conclusions: Once-weekly rhEPO therapy results in an improvement of erythropoiesis in a subset of MDS patients who are unresponsive to conventional dosing, and may act by inhibiting apoptosis of erythroid precursors. These results warrant further investigation of this dosing regimen either alone or in combination with other agents.
Key words: apoptosis, erythropoietin, myelodysplastic syndrome, schedule
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Raza, N. Galili, S. Smith, J. Godwin, J. Lancet, M. Melchert, M. Jones, J. G. Keck, L. Meng, G. L. Brown, et al. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome Blood, June 25, 2009; 113(26): 6533 - 6540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis Oncologist, October 1, 2007; 12(10): 1264 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stasi, E. Abruzzese, G. Lanzetta, E. Terzoli, and S. Amadori Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes Ann. Onc., December 1, 2005; 16(12): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|